U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C19H16N8O
Molecular Weight 372.3833
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-04217903

SMILES

OCCN1C=C(C=N1)C2=CN=C3N=NN(CC4=CC5=CC=CN=C5C=C4)C3=N2

InChI

InChIKey=PDMUGYOXRHVNMO-UHFFFAOYSA-N
InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2

HIDE SMILES / InChI

Molecular Formula C19H16N8O
Molecular Weight 372.3833
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901

PF-04217903 is a triazolopyrazine inhibitor of c-MET that displays anticancer chemotherapeutic and anti-metastatic activities. PF-04217903 inhibits cell proliferation, invasion, and migration as well as tumor growth in various cancer models. In animal models of pancreatic neuroendocrine tumors, this compound prevents lymph node metastasis. PF-04217903 had been in phase I clinical trials by Pfizer for the treatment of solid tumors. In 2011, the company discontinued the development of the compound.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.8 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
397 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.24 μg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1595 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.81 μg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.6 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
16%
unknown
PF-04217903 plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
16.4%
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04217903 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg single, oral
Studied dose
Dose: 30 mg
Route: oral
Route: single
Dose: 30 mg
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.
2010 Aug
Patents

Sample Use Guides

Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Route of Administration: Oral
Treatment with 100 nM of PF-04217903 for 4 hours resulted in decreased p-MET, pERK, p-AKT and p-PLCγ1 in mouse melanocytes expressing TRIM4-MET or ZKSCAN1-MET
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:55:51 GMT 2025
Edited
by admin
on Mon Mar 31 20:55:51 GMT 2025
Record UNII
CYJ9ATV1IJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-04217903
Common Name English
MET TYROSINE KINASE INHIBITOR PF-04217903
Preferred Name English
PF-4217903
Code English
2-(4-(1-(QUINOLIN-6-YLMETHYL)-1H-(1,2,3)TRIAZOLO(4,5-B)PYRAZIN-6-YL)-1H-PYRAZOL-1-YL)ETHANOL
Systematic Name English
1H-PYRAZOLE-1-ETHANOL, 4-(1-(6-QUINOLINYLMETHYL)-1H-1,2,3-TRIAZOLO(4,5-B)PYRAZIN-6-YL)
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C143099
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
NCI_THESAURUS C129825
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
Code System Code Type Description
CAS
956905-27-4
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
PUBCHEM
17754438
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
DRUG BANK
DB12848
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
FDA UNII
CYJ9ATV1IJ
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID401026097
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
SMS_ID
300000041325
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL2001019
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
NCI_THESAURUS
C78483
Created by admin on Mon Mar 31 20:55:51 GMT 2025 , Edited by admin on Mon Mar 31 20:55:51 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
OFF TARGET->WEAK INHIBITOR
IC50
SALT/SOLVATE -> PARENT
OFF TARGET->WEAK INHIBITOR
No cardiac toxicity seen in clinical trials
IC50
OFF TARGET->WEAK INHIBITOR
IC50
TARGET -> INHIBITOR
Ki
Related Record Type Details
ACTIVE MOIETY